Searched for
RANEXA
Glenmark gets final nod from USFDA for angina treatment drugThe product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths.- Sell Lupin, target Rs 800: Elara CapitalSell Lupin at a price target of Rs 800.
- Banks, oil and gas majors may lead 15-20% earnings growth this quarter: Mayuresh JoshiThe markets might remain very volatile in shor term, says the Angel Broking fund manager
- Lupin launches chronic angina treatment drug in the USThe newly launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences' Ranexa ER tablets, Lupin said.
- Buy Lupin, target Rs 985: HDFC SecuritiesBuy Lupin at a price target of Rs 985.
- Buy Lupin, target Rs 1,030: HDFC SecuritiesBuy Lupin at a price target of Rs 1030.
- Lupin still on track to meet $800-million FY19 sales target: Ramesh SwaminathanThings not as bad as they were in the past and should be looking better, says Lupin CFO.
- For every rupee depreciation, we expect to add Rs 40 cr to bottom line: Ramesh Swaminathan, Lupin“Between 25% and 30% of our total exposures are hedged.”
- Good home show to help Lupin limit fallout of US woesIndian pharmaceutical cos are facing regulatory issues and steep competition in US market.
- Buy Lupin, target Rs 1190: HDFC SecuritiesBuy Lupin Ltd. at a price target of Rs 1190.
- Lupin gets USFDA nod for heart disease drugAccording to IMS Health data, the tablets posted sales of around $ 443.4 million in the US for the twelve months ending March, 2013.
- Credit Suisse downgrades Lupin, cites unfavourable risk rewardCredit Suisse has downgraded Lupin from ‘outperform’ to ‘neutral’ rating as risk reward appears unfavourable, Asia Pacific-focused broker s...
Load More
